isoxazoles has been researched along with Disease Exacerbation in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.33) | 18.2507 |
| 2000's | 26 (43.33) | 29.6817 |
| 2010's | 29 (48.33) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kan, HP; Tan, JH; Zhang, GW; Zhou, L | 1 |
| Kowdley, KV; Shah, RA | 1 |
| Deng, Y; Ding, TB; Dong, JB; He, SH; Hu, JC; Jiang, XC; Lou, B; Mo, MG; Yang, JT; Ye, DY; Yu, K; Zhou, L | 1 |
| Ahirwar, DK; Charan, M; Chatterjee, N; Das, S; Ganju, RK; Kaul, K; Mishra, S; Misri, S; Satoskar, AR; Varikuti, S | 1 |
| Cao, L; Che, X; Fang, W; Gu, L; Min, L; Mou, S; Ni, Z; Qian, J; Wang, L; Wang, Q; Yu, Z; Yuan, J; Zhang, M; Zhou, W; Zhu, M | 1 |
| Chow, MD; Guo, GL; Lee, YH | 1 |
| Chen, Z; Li, L; Li, S; Yang, Y; Zhang, L | 1 |
| Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC | 1 |
| Deng, Y; Huang, J; Liu, S; Lu, Y; Ning, G; Shen, W; Wang, H; Yang, J; Yang, Y; Zhang, D; Zhang, Q; Zhang, R; Zhu, R | 1 |
| Hirobe, M; Nishinaka, K; Sato, S; Takahashi, S; Tsukamoto, T | 1 |
| Koliutskaia, EV; Smulevich, AB | 1 |
| Alasti, F; Aletaha, D; Smolen, JS | 1 |
| Arstila, L; Elfving, P; Kaipiainen-Seppänen, O; Kononoff, A; Koskela, H; Rutanen, J | 1 |
| Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T | 1 |
| Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z | 1 |
| Fautrel, B; Gaujoux-Viala, C; Tsonaka, R; van der Helm-van Mil, AH; van Nies, JA | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| Alibaz-Oner, F; Direskeneli, H | 1 |
| Böttcher, J; Hansch, A; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G | 1 |
| Aglietta, M; Ahmed, S; Akimov, M; Alba, E; Armstrong, AC; Beck, JT; Biganzoli, L; Campone, M; Hsu Schmitz, SF; Kong, A; Lee, SC; Lefebvre, C; López López, R; Rea, D | 1 |
| Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS | 1 |
| Choi, JW; Jun, HS; Jung, JY; Li, HY; Oh, YS | 1 |
| Sizova, L | 1 |
| Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ | 1 |
| Mimori, T; Yukawa, N | 1 |
| Böhler, T; Canivet, C; Galvani, S; Gandia, P; Guilbeau-Frugier, C; Kamar, N; Mengelle, C; Negre-Salvayre, A; Rostaing, L; Salvayre, R; Thomsen, M | 1 |
| Katayama, K; Matsuno, T | 1 |
| Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F | 1 |
| Jiang, T; Levi, M; Wang, XX | 1 |
| Karjalainen, A; Pettersson, T | 1 |
| Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V | 1 |
| Morozova, MA | 1 |
| Badescu, GM; Bidzan, L; Hoeben, D; Jukić, V; Lahaye, M; Maciulis, V; Schmauss, M; Schreiner, A; Siracusano, A; Tessier, C | 1 |
| Hintz, E; Klein, R; Staehler, G | 1 |
| Anastasilakis, AD; Kapetanos, GA; Sakellariou, GT; Sayegh, FE | 1 |
| Combe, B; Fautrel, B; Granger, B; Guillemin, F; Le Loet, X; Saraux, A | 1 |
| Brandt-Jürgens, J | 1 |
| Breedveld, FC; Eberl, G; Emery, P; Kalden, JR; Schiff, MH; Smolen, JS; Tugwell, P; van Riel, PL | 1 |
| Ory, PA | 1 |
| Kalden, J; Scott, D; Smolen, J; Strand, V; van der Heijde, D | 1 |
| van der Heijde, DM | 1 |
| Issa, SN; Ruderman, EM | 1 |
| Hartmann, JT; Kanz, L; Kopp, HG; Moerike, K | 1 |
| Chen, FP; Davis, IC; Fortenberry, JA; Graves, LM; Hickman-Davis, JM; Lazarowski, ER; Matalon, S; Sorscher, E; Sullender, WM; Zhao, X | 1 |
| Badesch, D; Barst, RJ; Frost, A; Galie, N; Langleben, D; Lawrence, EC; Naeije, R; Shapiro, S | 1 |
| Bordet, JC; Boucharaba, A; Clézardin, P; Guglielmi, J; Peyruchaud, O; Serre, CM | 1 |
| Aleksandrova, EN; Balabanova, RM; Kashevarov, RIu; Oliunin, IuA; Smirnov, AV | 1 |
| Saito, E; Suwa, A; Suzuki, Y; Wakabayashi, T | 1 |
| Deng, M; Heemann, U; Huang, H; Lutz, J; Roos, M; Schmaderer, C; Strobl, M; Wagner, B | 1 |
| Dehler, S; Finckh, A; Gabay, C | 1 |
| Park, MH | 1 |
| Beuers, U; Budenhofer, U; Kremer, AE; Rust, C | 1 |
| Kaplowitz, N; Kuhlenkamp, J; Lu, SC; Stone, L; Sun, WM; Wu, H | 1 |
| Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS | 1 |
| Hurley, F; Leung, H; Loew-Friedrich, I; Sharp, JT; Strand, V | 1 |
| Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F | 1 |
| Beattie, BJ; Blasberg, RG; Malkin, MG; Thiessen, B; Vlassenko, AG | 1 |
| Debroe, S; Hewitson, PJ; McBride, A; Milne, R | 1 |
| Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R | 1 |
| Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB | 1 |
14 review(s) available for isoxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Topics: Azepines; Bile Acids and Salts; Carcinoma, Hepatocellular; Disease Progression; Energy Metabolism; Gene Expression Regulation; Glucose; Humans; Indoles; Isoxazoles; Liver; Liver Cirrhosis; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Receptors, Steroid | 2017 |
Update on Takayasu's arteritis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Diagnostic Imaging; Disease Management; Disease Progression; Humans; Isoxazoles; Leflunomide; Prevalence; Prognosis; Severity of Illness Index; Takayasu Arteritis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Quality of Life; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Therapy, Combination; Gold Sodium Thiomalate; Humans; Isoxazoles; Leflunomide; Methotrexate; Penicillamine; Radiography; Randomized Controlled Trials as Topic; Sulfasalazine; Tacrolimus | 2009 |
Nuclear hormone receptors in diabetic nephropathy.
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Heat-Shock Proteins; Hepatocyte Nuclear Factor 4; Humans; Hypolipidemic Agents; Isoxazoles; Liver X Receptors; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Receptors, Calcitriol; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Thiazolidinediones; Transcription Factors; Vitamin D | 2010 |
[Diagnosis and management of small vessel vasculitides].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Disease Progression; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Leflunomide; Methotrexate; Mycophenolic Acid; Plasmapheresis; Rituximab; Vasculitis | 2010 |
[Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].
Topics: Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia | 2012 |
Interpreting radiographic data in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sialoglycoproteins; Treatment Outcome | 2003 |
Overview of radiologic efficacy of new treatments.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Radiography; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sialoglycoproteins; Treatment Outcome | 2004 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Factors; Isoxazoles; Leflunomide; Methotrexate; Sulfasalazine | 2004 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progression; Humans; Isoxazoles; Joints; Leflunomide; Methotrexate; Radiography; Remission Induction; Sulfasalazine | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Costs; Humans; Isoxazoles; Leflunomide; Pain; Treatment Outcome | 2000 |
14 trial(s) available for isoxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide; Male; Platelet Aggregation Inhibitors; Proteinuria; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Valine; Valsartan | 2015 |
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Resorcinols; Trastuzumab; Treatment Outcome | 2016 |
Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Topics: Adolescent; Adult; Aged; Biopsy; Disease Progression; Female; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide; Lupus Nephritis; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2008 |
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Risk; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Precision Medicine; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Young Adult | 2012 |
Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Long-Term Care; Radiography; Treatment Outcome | 2004 |
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Risk Assessment; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
[An antidestructive effect of leflunomide in early rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Severity of Illness Index; Treatment Outcome | 2006 |
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Topics: Algorithms; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Middle Aged; Placebos; Radiography; Statistics, Nonparametric; Sulfasalazine; Treatment Outcome | 1999 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Isoxazoles; Leflunomide; Methotrexate; Placebos; Radiography; Sulfasalazine | 2000 |
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Outcome Assessment, Health Care; Radiography; Treatment Outcome | 2000 |
Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Radiography; Sulfasalazine; Treatment Outcome | 2001 |
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Confidence Intervals; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Isoxazoles; Leflunomide; Logistic Models; Male; Middle Aged; Radiography; Rheumatoid Factor; Statistics, Nonparametric; Sulfasalazine; Treatment Outcome | 2001 |
32 other study(ies) available for isoxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Parecoxib Improves the Outcomes of Acute Mild and Moderate Pancreatitis: A 3-Year Matched Cohort Study Based on a Prospective Database.
Topics: Acute Disease; Adult; Bacterial Infections; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Disease Progression; Female; Fever; Humans; Isoxazoles; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatitis; Protective Agents; Severity of Illness Index | 2019 |
Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Progression; Enzyme Inhibitors; Female; Gene Knockout Techniques; Humans; Immunity, Cellular; Isoxazoles; Macrophage Activation; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Prognosis; Transferases (Other Substituted Phosphate Groups); Triple Negative Breast Neoplasms | 2021 |
Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Topics: Animals; Apoptosis; Caspases; Cell Movement; Cell Survival; Cytochromes c; Disease Progression; Enzyme Activation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inflammation; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Metastasis; Neoplasm Transplantation; Treatment Outcome; Triple Negative Breast Neoplasms; Wound Healing | 2020 |
Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Biomarkers; Blood Pressure; Disease Progression; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Isoxazoles; Kaplan-Meier Estimate; Leflunomide; Male; Middle Aged; Proteinuria; Treatment Outcome | 2017 |
COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.
Topics: Animals; Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Endothelial Cells; Female; Glucose; Glycolysis; Isoxazoles; Mice, Inbred C57BL; Neoplasms; Ovarian Neoplasms; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2018 |
Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Advanced Oxidation Protein Products; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Case-Control Studies; Disease Progression; Female; Gene Expression; Humans; Isoxazoles; Leflunomide; Lipid Peroxides; Male; Metabolic Syndrome; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Sex Factors; Uric Acid | 2018 |
Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis.
Topics: Animals; Cells, Cultured; Chemokines; Disease Progression; Down-Regulation; Fatty Liver; Gene Expression Regulation; HEK293 Cells; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear | 2013 |
[Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy].
Topics: Anticonvulsants; Child; Dehydration; Disease Progression; Epilepsy, Tonic-Clonic; Female; Humans; Hydronephrosis; Isoxazoles; Nephrostomy, Percutaneous; Stents; Time Factors; Treatment Outcome; Ureter; Urolithiasis; Zonisamide | 2013 |
[Maintenance treatment of schizophrenia with paliperidone palmitate (xeplion): a naturalistic study].
Topics: Adult; Antipsychotic Agents; Disease Progression; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2013 |
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Female; Finland; Humans; Incidence; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Prognosis; Risk Assessment; Sampling Studies; Survival Rate | 2014 |
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Radiography; Retrospective Studies; Tacrolimus; Treatment Outcome | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort Studies; Disease Progression; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Proportional Hazards Models; Remission Induction; Sulfasalazine; Time-to-Treatment; Treatment Outcome | 2015 |
Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone Density; Disease Progression; Female; Germany; Hand Joints; Humans; Isoxazoles; Leflunomide; Longitudinal Studies; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Arthritis; Cyclophosphamide; Disease Progression; Female; Hematologic Diseases; Humans; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Middle Aged; Pain; Prognosis; Raynaud Disease; Recurrence; Scleritis; Serositis; Treatment Outcome; Triamcinolone Acetonide; Uveitis; Vision Disorders | 2016 |
Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
Topics: Animals; Cell Line; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Glycogen Synthase Kinase 3 beta; Isoxazoles; Kidney Cortex; Lysophospholipids; Male; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Phosphorylation; Propionates; Receptors, Lysophosphatidic Acid; RNA Interference; Signal Transduction; Smad2 Protein; Smad3 Protein; Sterol Regulatory Element Binding Protein 1; Time Factors; Transfection; Transforming Growth Factor beta | 2017 |
Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome.
Topics: Adult; Aged; Antigens, CD; BK Virus; Cell Proliferation; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Humans; Immunosuppressive Agents; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Isoxazoles; Kidney; Kidney Transplantation; Leflunomide; Male; Middle Aged; Mycophenolic Acid; Nephritis; Polyomavirus Infections; Receptors, Transferrin; T-Lymphocytes; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Finger Joint; Humans; Isoxazoles; Japan; Leflunomide; Male; Methotrexate; Middle Aged; Radiography; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Toe Joint; Treatment Outcome; Wrist Joint | 2009 |
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2011 |
Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Topics: Autoantibodies; Autoantigens; Disease Progression; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Hepatitis, Autoimmune; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2012 |
Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retreatment; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2013 |
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Cohort Studies; Disease Progression; Female; Humans; Isoxazoles; Leflunomide; Logistic Models; Male; Methotrexate; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Peptides, Cyclic; Prognosis; Radiography | 2012 |
[Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Disease Progression; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Expert Testimony; Female; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Isoxazoles; Leflunomide; Methotrexate; National Health Programs; Off-Label Use; Prednisolone; Tumor Necrosis Factor Inhibitors | 2013 |
A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Health Status Indicators; Humans; Isoxazoles; Joints; Leflunomide; Linear Models; Male; Middle Aged; Pain Measurement; Severity of Illness Index; Treatment Outcome | 2003 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Isoxazoles; Leflunomide; Male; Peripheral Nervous System Diseases; Polyneuropathies; Rectal Neoplasms; Tegafur; Time Factors; Uracil | 2005 |
Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Disease Progression; Female; Isoxazoles; Leflunomide; Lung; Male; Mice; Mice, Inbred BALB C; Nucleotidases; Pneumonia, Viral; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Severity of Illness Index | 2006 |
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Lysophospholipids; Mice; Neoplasm Metastasis; Osteoclasts; Propionates; Receptors, Lysophosphatidic Acid | 2006 |
The effect of FK778 on the progression of chronic allograft nephropathy in a rat model.
Topics: Alkynes; Animals; Creatinine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Graft Rejection; Immunosuppressive Agents; Isoxazoles; Kidney; Kidney Transplantation; Male; Nitriles; Proteinuria; Proto-Oncogene Proteins c-sis; Rats; Rats, Inbred F344; Rats, Inbred Lew; RNA, Messenger; Transforming Growth Factor beta; Transplantation, Homologous | 2007 |
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Topics: Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Confounding Factors, Epidemiologic; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Longitudinal Studies; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
[A 47-year-old dog breeder with chronic polyarthritis, weight loss and high fever].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Disease Progression; Fever of Unknown Origin; Humans; Immunologic Deficiency Syndromes; Isoxazoles; Leflunomide; Male; Middle Aged; Polymerase Chain Reaction; Risk Factors; Systemic Inflammatory Response Syndrome; Tropheryma; Weight Loss; Whipple Disease | 2008 |
Progressive defect in biliary GSH secretion in streptozotocin-induced diabetic rats.
Topics: Animals; Bile; Diabetes Mellitus, Experimental; Disease Progression; Enzyme Inhibitors; gamma-Glutamyltransferase; Glutathione; Isoxazoles; Liver; Male; Perfusion; Protein Kinase C; Rats; Rats, Sprague-Dawley | 1997 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biological Transport, Active; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Energy Metabolism; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Glioblastoma; Glucose; Humans; Isoxazoles; Leflunomide; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Prognosis; Signal Transduction; Supratentorial Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2000 |